The drug is intended to treat adults with advanced or metastatic breast cancer that has progressed despite prior treatment. Verzenio may be used in combination with the endocrine therapy, fulvestrant, or as a stand-alone treatment.
The drug will cost $10,948 a month before any discounts or rebates, according to Reuters. Eli Lilly will offer a special savings card program, in which commercially insured patients can receive the first three months of therapy free, and then pay a maximum of $10 per month for up to a year.
Eli Lilly plans to launch the drug by the end of October.
More articles on supply chain:
AmerisourceBergen fined $260M over cancer drug packaging: 4 things to know
Millennials least likely to comply with recall notices, study finds
A proactive approach to drug shortages: 6 strategies from Advocate Health Care’s director of central service pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
